Risks and benefits: new concepts of treatment of late-onset hypogonadism.
- Author:
Xue-Jun SHANG
;
Yu-Feng HUANG
- Publication Type:Journal Article
- MeSH:
Humans;
Hypogonadism;
drug therapy;
surgery;
therapy;
Male;
Testosterone;
therapeutic use
- From:
National Journal of Andrology
2014;20(6):483-489
- CountryChina
- Language:Chinese
-
Abstract:
Late-onset hypogonadism (LOH) is a clinical and bio-chemical syndrome associated with advancing age in males and seriously affects the quality of life of some of the patients. A classical therapeutic option for LOH is testosterone supplementary treatment (TST). Its effectiveness has been verified, whereas its long-term safety remains to be further evaluated. With deeper insights into LOH, many new therapeutic strategies have been proposed, which include the treatments with gonadotropins, testosterone precursors (such as dehydroepiandrosterone [DHEA]), non-aromatizable androgens (such as dihydrotestosterone [DHT]), antiestrogens (such as aromatase inhibitors and estrogen receptor antagonists), and Chinese medicine. Meanwhile, studies on the transplantation of Leydig stem cells, selective androgen receptor modulators (SARMs), and selective estrogen receptor beta (ERbeta) agonists have shed new light on the treatment of LOH.
